Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

779
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
779
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

870
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
870
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

656
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
656
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

616
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
616
Peripheral Nervous System: Ganglia and Nerves01:24

Peripheral Nervous System: Ganglia and Nerves

5.4K
The Peripheral Nervous System (PNS) is a crucial component of the body's neural network, extending beyond the central nervous system (CNS) to bridge the gap between the CNS and the external environment. It encompasses nerves, ganglia, and sensory receptors.
Nerves
The nerve is a bundle of axons that serves as the communication highway in the PNS. Each nerve is ensheathed in a protective layer of connective tissue called the epineurium. This outermost layer safeguards the nerve and supports the...
5.4K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

375
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
375

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient, care partner, and oncologist perspectives on clinically important survival thresholds after considering time toxicity in advanced cancer.

The oncologist·2026
Same author

Power wheelchair vendors: Declines in rural market activity.

Disability and health journal·2026
Same author

Healthcare contact days in cancer survivors relative to those with no cancer history.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Cluster analysis identifies high-risk phenotypic groups for revision following 1-3 level lumbar fusion in a disadvantaged inner-city population.

North American Spine Society journal·2026
Same author

Characteristics, Management, and Outcomes of Diabetes Subtypes in Patients With Cardiogenic Shock: A Nationwide Analysis.

JACC. Advances·2026
Same author

Counting What Counts in Cancer Operation.

Journal of the American College of Surgeons·2026
Same journal

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

JAMA oncology·2026
Same journal

Cardiac Risk After Heart-Sparing Breast Radiotherapy.

JAMA oncology·2026
Same journal

When Not to Push the Boulder.

JAMA oncology·2026
Same journal

Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis.

JAMA oncology·2026
Same journal

Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast Cancer.

JAMA oncology·2026
Same journal

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA oncology·2026
See all related articles

Related Experiment Video

Updated: Jan 28, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K

Chemotherapy-Induced Peripheral Neuropathy

Timothy J Brown, Ramy Sedhom, Arjun Gupta

    JAMA Oncology
    |March 1, 2019
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies
    11:29

    Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies

    Published on: January 3, 2011

    27.3K
    Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
    08:56

    Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

    Published on: October 7, 2021

    3.3K

    Related Experiment Videos

    Last Updated: Jan 28, 2026

    Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
    07:42

    Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

    Published on: April 26, 2012

    18.6K
    Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies
    11:29

    Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies

    Published on: January 3, 2011

    27.3K
    Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
    08:56

    Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

    Published on: October 7, 2021

    3.3K